- Home
- HOLO vs ANTX Comparison
HOLO vs ANTX Comparison
Compare HOLO & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOLO | ANTX |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | China | United States |
| Employees | 64 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.2M | 36.7M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | HOLO | ANTX |
|---|---|---|
| Price | $2.15 | $5.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 341.0K | ★ 508.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $1.00 |
| 52 Week High | $12.75 | $2.97 |
Technical Indicators
Market Signals| Indicator | HOLO | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.59 | 96.93 |
| Support Level | $2.02 | $1.05 |
| Resistance Level | $2.30 | N/A |
| Average True Range (ATR) | 0.12 | 0.42 |
| MACD | 0.02 | 0.35 |
| Stochastic Oscillator | 24.00 | 73.07 |
Price Performance
Historical ComparisonAbout HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.